Osilodrostat (LCI699) - 99%, high purity , CAS No.928134-65-0, Inhibitor of CYP11B1;Inhibitor of CYP11B2

Item Number

O413758

• Synonyms: (R)-4-(6,7-Dihydro-5H-pyrrolo(1,2-c)imidazol-5-yl)-3-fluorobenzonitrile | GTPL8310 | 5YL4IQ1078 | OSILODROSTAT [WHO-DD] | Osilodrostat free base | Osilodrostat;4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile | TRICLOCARBAN (USP MO
• Specifications & Purity: Moligand™, ≥99%
• Biochemical and Physiological Mechanisms: LCI699(Osilodrostat) is a potent inhibitor of 11β-hydroxylase (CYP11B), an enzyme catalyzing the final step of cortisol synthesis.
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: INHIBITOR
• Mechanism of action: Inhibitor of CYP11B1;Inhibitor of CYP11B2

Product Description

Information

Osilodrostat (LCI699) LCI699(Osilodrostat) is a potent inhibitor of 11β-hydroxylase (CYP11B) , an enzyme catalyzing the final step of cortisol synthesis.

Targets

11β-hydroxylase 2.5 nM

In vitro

LCI699 also inhibits aldosterone synthase (CYP11B2) other than CYP11B1.

In vivo

LCI699 is a potent inhibitor of 11β-hydroxylase (CYP11B1), the enzyme that catalyzes the final step of cortisol synthesis, and has a half-life of ∼4 hours. It decreases blood pressure (BP) in patients with essential hypertension and primary aldosteronism. Treatment with LCI699 is well tolerated, it is demonstrated efficacy with a satisfactory safety and tolerability profile in the proof-of-concept study in Cushing\'s disease. The administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism.